India Medical Device Regulators: CDSCO, CLA and SLA

1. Key takeaways

Medical devices in India are regulated by a single national regulator operating through two tiers of licensing authorities. The Central Drugs Standard Control Organisation (CDSCO) is the competent authority, and its headquarters, acting as the Central Licensing Authority (CLA), is responsible for all import licences and for manufacturing licences covering Class C and Class D devices. The state drugs control authorities, acting as the State Licensing Authorities (SLA), are responsible for manufacturing licences covering Class A and Class B devices and for wholesale registration certificates. The single most important point for foreign enterprises is that the import stage is approved by the CLA regardless of the risk class of the device. This is the point that overseas companies most frequently miscalculate when they plan their Indian market entry, because the instinct to deal with a lower-risk device at a local level simply does not apply to imports.

• CDSCO is the national regulator; its headquarters functions as the CLA.
• The CLA approves every import licence, whatever the device class.
• The SLA handles Class A/B manufacturing licences and wholesale registration.
• Manufacturing approvals are split by risk class; import approvals are not.
• State-level practice varies, so current SLA practice must be confirmed locally.

2. Legal basis

The allocation of responsibilities described above is not an administrative convention but is anchored in specific legal provisions. The table below summarises the legal sources that govern who regulates what, from the parent statute through the Medical Devices Rules 2017 to the official CDSCO interpretations published in its FAQ document. Every duty, application and licence touched elsewhere in this guide traces back to one of these entries, which is why a compliance plan for India should begin by confirming the applicable entry for each planned activity rather than by preparing documents first.

3. Expert insights

Insight one: the three-level structure is not a tiered delegation of the same power but a division by activity. Many enterprises assume that a low-risk Class A device is handled by the state level across the board, and they therefore approach a state authority for the import stage as well. In reality, the risk-based split applies to the manufacturing stage only; the import stage is entirely centralised at the CLA. A Chinese company exporting a Class A sterile device to India must still have its Indian agent file an MD-14 application with the CLA. Reading the class as a shortcut to the wrong authority wastes months and can expose the importer to enforcement action, because the application will simply not be entertained by the body it was sent to.

Insight two: CDSCO wears three hats at once. It is the enforcement body for the Rules (CDSCO headquarters = the CLA), it is the body that decides classification questions (Rule 3), and it is the registration authority for notified bodies (Rule 13, registration certificate Form MD-2). The practical consequence is that a single technical judgement may pass through three of its checkpoints in sequence, so the technical storyline presented in the dossier must be consistent from beginning to end. A classification described one way in a filing and another way in a label submission invites questions that are entirely avoidable.

Insight three: the SLA is not a lower-tier copy of the CLA but a separate administrative system. India is a federal union, and the state drugs control authorities differ in their processing rhythm, the rigour of their site inspections and their expectations on documentary detail. For any matter that falls to the SLA, the reference point must always be the current practice of the state authority concerned, not a generic national assumption. This is why practical estimates involving SLA handling should be treated as a practical estimate pending verification against the state in question rather than as a fixed national standard.

4. Practical recommendations

• When GRZAN takes over an India project, the first task is to draw an authority map: is the product to be imported or manufactured locally, and who therefore holds the file?
• If the product is imported, route every class, from Class A to Class D, through the CLA via the Indian agent’s MD-14 filing.
• If manufacturing in India is planned, approach the SLA for Class A/B and CDSCO headquarters for Class C/D.
• If wholesale distribution is planned, file separately with the SLA for the MD-41 application leading to the MD-42 registration certificate.
• The licences can be pursued in parallel, but none of them substitutes for another; keep the scopes distinct in every plan and every agreement.
• Confirm the current practice of the specific state SLA before committing dates, and treat any internal estimate as a practical estimate pending verification.

5. Verification checklist

• □ The activity type — import, manufacture or wholesale — has been identified and matched to the corresponding authority.
• □ For import, the authorised Indian agent has been confirmed to file the MD-14 with the CLA.
• □ For manufacturing, the SLA or the CLA has been determined according to the risk class.
• □ For wholesale, the MD-41 application has been prepared for the SLA.
• □ The current acceptance practice of the relevant state SLA has been confirmed.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of 27 October 2026.